JAMA Reviews Hepatitis B: 254 Million Infected, New Treatments Cut Cancer Risk by Half
A comprehensive JAMA review covers HBV epidemiology, diagnosis, and antivirals that reduce hepatocellular carcinoma risk by ~50%.
Summary
Hepatitis B virus infects 254 million people globally and kills roughly 1.1 million annually. This JAMA review covers how HBV spreads, how it's diagnosed, and how it progresses to cirrhosis and liver cancer. Key points: birth-dose vaccination prevents 94% of perinatal infections, yet global coverage was only 45% in 2024. Antiviral drugs — entecavir and tenofovir — suppress viral replication and cut hepatocellular carcinoma risk by about 50%. Treatment is recommended for all patients with cirrhosis and for those without cirrhosis who have high viral loads plus elevated liver enzymes or significant fibrosis. High-risk patients should receive liver cancer surveillance every six months. The review underscores that better vaccination coverage and broader antiviral access are the two levers most likely to reduce the enormous global burden of this preventable disease.
Detailed Summary
Hepatitis B remains one of the most consequential infectious diseases on the planet, causing an estimated 1.1 million deaths each year despite the existence of a highly effective vaccine. This comprehensive review published in JAMA synthesizes current evidence on HBV epidemiology, transmission, natural history, diagnosis, and treatment to provide clinicians and public health practitioners with an up-to-date reference.
HBV is a DNA virus transmitted through blood, semen, or body fluids. Mother-to-child transmission is the dominant route globally, occurring in 70–90% of infants born to mothers who are both HBsAg and HBeAg positive. The younger a person is at infection, the higher the risk of chronicity: 90% of infected infants develop chronic infection versus just 5% or less of immunocompetent adults. Approximately 1.2 million new infections occurred worldwide in 2022, including 14,000 in the United States.
Diagnosis relies on serologic markers — HBsAg for active infection, anti-HBs for immunity, and anti-HBc for prior or ongoing exposure — combined with HBV DNA quantification. Liver fibrosis assessment using tools like the Fibrosis-4 index and elastography guides treatment decisions without requiring invasive biopsy.
Chronic HBV carries a 5-year cumulative cirrhosis risk of 8–15%, and among cirrhotic patients, annual hepatocellular carcinoma incidence reaches 3–5%. Antiviral therapy with pegylated interferon alfa or nucleos(t)ide analogues (entecavir or tenofovir) suppresses viral replication and reduces HCC risk by approximately 50%, representing a major clinical advance.
Despite these tools, global birth-dose vaccine coverage stood at only 45% in 2024 — far below what is needed to achieve elimination targets. The authors conclude that universal birth-dose vaccination combined with expanded antiviral access represents the most impactful path toward reducing HBV-related mortality worldwide. Caveats include the review's reliance on existing literature and the abstract-only availability for this summary.
Key Findings
- Antiviral therapy (entecavir or tenofovir) reduces hepatocellular carcinoma risk by approximately 50% in chronic HBV patients.
- Birth-dose HBV vaccination plus immune globulin prevents ~94% of perinatal infections; adding antivirals in high-viral-load mothers cuts transmission to under 1%.
- Global birth-dose HBV vaccine coverage was only 45% in 2024, far below elimination thresholds.
- Infants infected with HBV have a 90% chance of developing chronic infection versus ≤5% in immunocompetent adults.
- High-risk patients should receive liver ultrasound and AFP surveillance every 6 months to detect HCC early.
Methodology
This is a narrative review article published in JAMA, synthesizing existing epidemiological, clinical, and therapeutic evidence on hepatitis B. The authors represent major academic hepatology centers in Taiwan, Hong Kong, and the United States. As a review, it does not report original trial data but consolidates findings from prior studies and guidelines.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; nuanced recommendations and cited evidence cannot be fully evaluated. As a narrative review, it may reflect author selection bias in the literature included. The review does not appear to include formal systematic review or meta-analytic methodology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.